Eton Pharmaceuticals (ETON) Scheduled to Post Quarterly Earnings on Tuesday

Eton Pharmaceuticals (NASDAQ:ETON) will announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.05). The company had revenue of $9.07 million during the quarter, compared to the consensus estimate of $10.00 million. Eton Pharmaceuticals had a negative return on equity of 43.62% and a negative net margin of 21.31%. On average, analysts expect Eton Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Eton Pharmaceuticals Trading Up 1.3 %

ETON opened at $8.78 on Monday. The stock has a fifty day moving average price of $6.86 and a 200-day moving average price of $4.77. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $9.12. The firm has a market cap of $226.84 million, a price-to-earnings ratio of -33.77 and a beta of 1.25.

Analyst Upgrades and Downgrades

ETON has been the topic of several recent analyst reports. HC Wainwright upped their target price on Eton Pharmaceuticals from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Craig Hallum upped their target price on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Insider Activity at Eton Pharmaceuticals

In other news, major shareholder Opaleye Management Inc. acquired 57,500 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average cost of $4.65 per share, with a total value of $267,375.00. Following the completion of the acquisition, the insider now owns 2,660,000 shares of the company’s stock, valued at approximately $12,369,000. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have acquired 85,600 shares of company stock valued at $462,674 in the last ninety days. Corporate insiders own 14.89% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.